Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has shared an update.
ResMed Inc. disclosed that director and chairman emeritus Peter C. Farrell sold 2,000 shares of ResMed common stock on 7 January 2026 at a price of $248.83 per share under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the transaction, Farrell continues to hold 66,773 shares directly, indicating an ongoing, though slightly reduced, equity stake in the company by a long-standing board member, with no operational changes or strategic shifts signaled in the filing.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a medical technology company focused on developing and manufacturing devices and software for the diagnosis, treatment and management of sleep-disordered breathing and other chronic respiratory conditions, serving patients, healthcare providers and sleep clinics globally.
Average Trading Volume: 1,168,910
Technical Sentiment Signal: Buy
Current Market Cap: A$54.89B
See more insights into RMD stock on TipRanks’ Stock Analysis page.